Nuvalent Zidesamtinib Shows Strong NSCLC Trial Results
CAMBRIDGE, Mass., April 17, 2026 Nuvalent, Inc. has reported compelling clinical and preclinical data for its investigational drug zidesamtinib,...
AACR 2026
Advertisement
City of Hope Unveils AI and Cancer Breakthroughs at AACR
LOS ANGELES, April 16, 2026 City of Hope announced that its scientists will present groundbreaking research findings on cancer...
Fate Therapeutics FT839 CAR T Shows Strong Preclinical Data
SAN DIEGO, Calif., April 16, 2026 Fate Therapeutics, Inc. has announced the presentation of preclinical data for its next-generation...
Geminii Shows Promising NSCLC Data for Bioelectronic Therapy
CHICAGO, April 16, 2026 Geminii, Inc. has announced the presentation of new preclinical data on its bioelectronic therapy platform...
Personalis Advances ctDNA Cancer Monitoring with AI Platform
Fremont, California | April 13, 2026 Personalis, Inc. has unveiled new data showcasing its ultrasensitive ctDNA-based cancer monitoring platform,...
Advertisements
NeoGenomics Advances AI-Driven Oncology Insights at AACR
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
AnBogen Therapeutics Showcases ABT-301 Cancer Breakthroughs
TAIPEI, Taiwan, April 13, 2026 AnBogen Therapeutics has announced that its lead investigational therapy Imofinostat (ABT-301) will be featured...
Phanes Advances Spevatamig to Expansion in BTC Trial
SAN DIEGO, April 7, 2026 Phanes Therapeutics, Inc. has announced the initiation of the dose expansion phase in its...
MiNK Therapeutics Highlights Phase II iNKT Therapy at AACR
NEW YORK, April 3, 2026 MiNK Therapeutics announced that new Phase II clinical trial data for its investigational iNKT...
Agenus Showcases Phase II Cancer Immunotherapy Data at AACR
LEXINGTON, Mass., April 3, 2026 Agenus Inc. has announced that new data from its Phase II clinical study evaluating...
Advertisement
